This guidance recommends that abbreviated new drug applications (ANDAs) submitted under section 505(j) of the Federal Food, Drug and Cosmetic Act, and the drug master files (DMFs) that support ANDAs, follow the stability recommendations provided in the International Conference on Harmonisation (ICH) stability guidances.
Pharmacy / Pharmaceuticals:
Life cycle of medicinal products and medical devices:
Resource type:
Format:
Added by: Ekaterina Chashnikova
March 12, 2024
Description
Comments
![Share [FDA] ANDAs: Stability Testing of Drug Substances and Products](https://mymedpharm.info/wp-content/themes/medpharm/src/img/share.svg)
Copy link
E-mail
LinkedIn
Facebook
Telegram
WhatsApp
See also
Recognise, first by signing up to receive updates
